It is noteworthy that, in comparison to EGFR wild-type lung adenocarcinoma, immune-related pathways were upregulated in EGFR-mutated BM, even though no significant differences were observed in the primary tumors with EGFR mutations [78]. This evidence concerns the gene EGFR and lung adenocarcinoma.